Merck: reports encouraging results for new HIV treatment

(CercleFinance.com) - On Monday Merck presented additional data reinforcing the potential for experimental drug islatravir in combination with doravirine as a two-drug regimen for people living with HIV.


New analyses from a Phase 2b trial evaluating the safety and efficacy of islatravir in combination with doravirine demonstrated that participants who switched from 3TC to islatravir and doravirine maintained antiviral activity at week 48, the company said.

"These findings add to the growing body of evidence supporting the potential of islatravir and doravirine for the treatment of people living with HIV", Merck said.

The US drugmaker said it is now looking forward to learn more about this combination from an ongoing Phase 3 clinical trial.

Copyright (c) 2020 CercleFinance.com. All rights reserved.